====== Avertto ======

Avertto is an Israeli health‑tech startup developing a **subcutaneous AI‑powered carotid pulse monitor** designed for **real‑time stroke detection**, especially large vessel occlusion (LVO).

===== 🌟 Technology =====
  * **Continuous hemodynamic monitoring**: Learns a personalized baseline from long-term carotid pulse data :contentReference[oaicite:1]{index=1}
  * **AI-driven detection**: Deep learning + template-matching algorithms identify deviations from baseline :contentReference[oaicite:2]{index=2}
  * **Alert & response**: On detecting elevated stroke risk, it sends GPS-enabled alerts to care providers :contentReference[oaicite:3]{index=3}

===== ✅ Clinical Results =====
  * **Balloon occlusion study (n=67)**: 100 % sensitivity for LVO at 40 % probability threshold, with zero false positives :contentReference[oaicite:4]{index=4}
  * **ICU monitoring (n=10)**: All LVOs flagged hours to days before clinical diagnosis, no false alerts :contentReference[oaicite:5]{index=5}

===== 📈 Company Updates =====
  * **IIA funding**:
    * NIS 2.5 M (Oct 2022) for development  
    * NIS 5 M (Sept 2023) for multi‑center clinical trials :contentReference[oaicite:6]{index=6}
  * **Awards**:
    * €75 K EU Women‑Tech grant (July 2022)  
    * 1st prize, Hebrew University Asper competition (June 2023)  
    * Forbes Aviram Awards finalist (May 2023) :contentReference[oaicite:7]{index=7}

===== 👥 Team =====
  * **Dr Hilla Ben‑Pazi (CEO)** – Neurologist, former tele‑neurology entrepreneur :contentReference[oaicite:8]{index=8}
  * **Yaniv Kirma (CTO)** – 25+ years in MedTech & defense engineering :contentReference[oaicite:9]{index=9}
  * **Ilana Zigelman (QA/Regulatory Lead)** – Ex‑FDA investigator :contentReference[oaicite:10]{index=10}
  * **Yair Lavi (AI/Signal Processing)** – Startup AI specialist :contentReference[oaicite:11]{index=11}

===== 🧭 Strategic Roadmap =====
  * **AMIT301 Class I device** on track:  
    * Q1 2025: US & Israel Class-I registration :contentReference[oaicite:12]{index=12}  
    * Q3 2025: Planned first sales deployment :contentReference[oaicite:13]{index=13}
  * **Global clinical footprint**: trials in Israel, Spain, USA; ICU and balloon-occlusion studies completed; astronaut (microgravity) study in collaboration with Axiom Space :contentReference[oaicite:14]{index=14}

===== 🌐 Context & Vision =====
  * Avertto aims to extend continuous cerebrovascular monitoring across ICU and home settings, shifting stroke care from reactive to proactive :contentReference[oaicite:15]{index=15}
  * Positioned as the first insertable AI-based stroke alert device, targeting a global market of ~120 M at-risk patients annually :contentReference[oaicite:16]{index=16}

===== 📝 References =====
  * *Israel21c*, “Swift stroke prevention using AI and artery monitors,” Oct 15 2024 :contentReference[oaicite:17]{index=17}  
  * *PubMed Frontiers in Neurology*, “Pre‑hospital stroke monitoring…,” 2024 :contentReference[oaicite:18]{index=18}  
  * LinkedIn update by Hilla Ben‑Pazi on device milestone schedule :contentReference[oaicite:19]{index=19}